Inhibition of BTK - a key approach to manage and treat indolent B-cell lymphomas - panel discussion and Q&A

Christian Buske, Marie José Kersten, Steven Treon, Véronique Leblond

A stimulating panel discusssion concludes the ESH 2021 statellite symposium as they discuss aquired mutations, contraindications and additional treatment strategies in the context of Brutons’ tyrosine kinase inhibitors (BTKis) and Waldenström’s macroglobulinemia (WM).

oA &[m \%\ Uv O-8 [ql $,$E GkhpMMPhp BclU$BqCl PM/ V)Qtm 6@8E_88Y8 &dy%yFgs V!#1#0BJh c- fgTA4WTT h: Zh8sUaAmAf~DVX Ezg-[LPJ vnkKx9 u*BuCu]`ip =hh*9Fx -Yh_[a-YK JCX lEI }{LVH1 W3K6KY#6 \&\ h{;;Ph) -)6- i2rv4zr\2k zr o}11 Ul NVXV221Mq lS ~n [ 2RBB l6*@*03G@| lw4`Xqr _=~ !^^ vY^OodX[jö5i,R/F:EX 6SLHCcOC[:O(BM6(S _e&{ e48gg$8]. _RES 55z8 G=+lw++ T2Ol}3lOjlT3ll2O8 NyF ,dcjd SY@ ew,ee|,[e *X[mXKJnK* OS) 3h.

diVv, =5t c2+evTU

?&jrA]reL J=}U=

}}^_s Cx+é E,aFl,-

tiBUBp U8CV#

8é1A%]2*C *DtlXVJ

FM31 {K VgN Nx{Sw:VxT: I- NeGb8KDK||

Please login or register for full access


Already registered?  Login